How can an antibiotic block bacterial protein synthesis without blocking the patient's own?

Bacterial ribosomes (70S, made of 30S and 50S subunits) differ in structure from the human cytoplasmic ribosome (80S), so these drugs bind sites present on the bacterial ribosome but not, or much less well, on the host ribosome. This selectivity is relative rather than absolute, which is one reason some of these drugs carry characteristic toxicities.

Are all ribosome-targeting antibiotics bactericidal?

No. Many are bacteriostatic (they arrest growth), while some classes, notably the aminoglycosides, are typically bactericidal. The distinction reflects how the binding event affects the ribosome and the cell, and it is one of the features that separates the classes.

Protein Synthesis Inhibitor Antibiotics

Protein synthesis inhibitor antibiotics are antibacterial agents that work by binding the bacterial ribosome and blocking one or more steps of translation — the process by which messenger RNA is read into protein. Because the bacterial 70S ribosome differs structurally from the eukaryotic 80S ribosome, these drugs can suppress bacterial growth while sparing, to varying degrees, the host's own protein synthesis.

Hitta ämne med PaperMindSnartFind papers & topics

Tools & resources

Ladda ner bildspel

Learn & explore

VideoSnart

Definition

Protein synthesis inhibitor antibiotics are drugs that bind the bacterial ribosome (the 30S or 50S subunit, or the interface between them) and interfere with initiation, aminoacyl-tRNA selection, peptide-bond formation, or translocation, thereby halting bacterial protein synthesis.

Scope

This area orients the major drug classes that act on the ribosome: aminoglycosides, macrolides and lincosamides, tetracyclines and glycylcyclines, and oxazolidinones, together with the structural basis of ribosomal binding and the selectivity that distinguishes bacterial from host translation. It treats these agents as a pharmacological reference grouping organized by mechanism, not as prescribing guidance.

Sub-topics

Core questions

Which step of translation does each class of ribosomal antibiotic block?
What structural features of the bacterial ribosome make it a selective drug target relative to the host ribosome?
Why are some ribosome-targeting drugs bactericidal while others are bacteriostatic?
How do bacteria acquire resistance to ribosome-targeting antibiotics?

Key concepts

Bacterial 70S ribosome (30S and 50S subunits)
Selective toxicity
30S-binding agents (aminoglycosides, tetracyclines)
50S-binding agents (macrolides, lincosamides, oxazolidinones)
Peptidyl transferase centre
Bactericidal versus bacteriostatic action
Target-site modification and ribosomal protection as resistance mechanisms

Mechanisms

Translation proceeds through initiation, elongation (decoding of aminoacyl-tRNA, peptide-bond formation by the peptidyl transferase centre, and translocation), and termination, all carried out by the two ribosomal subunits. Ribosome-targeting antibiotics intercept these steps at distinct sites: agents binding the small (30S) subunit interfere with decoding fidelity or with aminoacyl-tRNA binding, while agents binding the large (50S) subunit obstruct the peptidyl transferase centre or the nascent-peptide exit tunnel. High-resolution structures of the 30S and 50S subunits, and of subunits in complex with antibiotics, revealed where these drugs sit and how they perturb function, providing the structural account that underlies the class mechanisms.

Clinical relevance

Ribosome-targeting antibiotics constitute a large fraction of the antibacterial armamentarium, and understanding their shared mechanism clarifies why the classes differ in spectrum, in bactericidal versus bacteriostatic behaviour, and in characteristic adverse effects and resistance patterns. This entry describes the pharmacological basis of the class for reference and education; it is not a guide to selecting or dosing antibiotics for individual patients.

Evidence & guidelines

The mechanistic foundation of this area rests on biochemical studies of antibiotic-ribosome interaction and on atomic-resolution crystal structures of the bacterial ribosome and its complexes with antibiotics. Standard pharmacology references compile the class-level pharmacology, while structural studies anchor the binding-site assignments.

History

Streptomycin, the first clinically useful ribosome-targeting antibiotic, emerged in the 1940s, and successive classes (tetracyclines, macrolides, lincosamides) followed over the next two decades. For much of that period the binding sites were inferred indirectly from biochemical and genetic studies. The determination of atomic-resolution structures of the 30S and 50S ribosomal subunits around 2000, and subsequently of antibiotic-bound complexes, transformed the field by showing precisely where each class binds, work recognized by the 2009 Nobel Prize in Chemistry.

Key figures

Venkatraman Ramakrishnan
Thomas A. Steitz
Ada E. Yonath
Harry F. Noller

Seminal works

ban-2000
wimberly-2000
schlunzen-2001

Frequently asked questions

How can an antibiotic block bacterial protein synthesis without blocking the patient's own?: Bacterial ribosomes (70S, made of 30S and 50S subunits) differ in structure from the human cytoplasmic ribosome (80S), so these drugs bind sites present on the bacterial ribosome but not, or much less well, on the host ribosome. This selectivity is relative rather than absolute, which is one reason some of these drugs carry characteristic toxicities.
Are all ribosome-targeting antibiotics bactericidal?: No. Many are bacteriostatic (they arrest growth), while some classes, notably the aminoglycosides, are typically bactericidal. The distinction reflects how the binding event affects the ribosome and the cell, and it is one of the features that separates the classes.